- Home
- ACCS vs ELUT Comparison
ACCS vs ELUT Comparison
Compare ACCS & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCS
- ELUT
- Stock Information
- Founded
- ACCS 1988
- ELUT 2015
- Country
- ACCS United States
- ELUT United States
- Employees
- ACCS N/A
- ELUT N/A
- Industry
- ACCS Publishing
- ELUT Medical Specialities
- Sector
- ACCS Consumer Discretionary
- ELUT Health Care
- Exchange
- ACCS Nasdaq
- ELUT Nasdaq
- Market Cap
- ACCS 34.4M
- ELUT 38.2M
- IPO Year
- ACCS N/A
- ELUT 2020
- Fundamental
- Price
- ACCS $8.50
- ELUT $0.72
- Analyst Decision
- ACCS Strong Buy
- ELUT Strong Buy
- Analyst Count
- ACCS 1
- ELUT 2
- Target Price
- ACCS $14.00
- ELUT $7.00
- AVG Volume (30 Days)
- ACCS 14.7K
- ELUT 250.5K
- Earning Date
- ACCS 11-11-2025
- ELUT 11-06-2025
- Dividend Yield
- ACCS N/A
- ELUT N/A
- EPS Growth
- ACCS N/A
- ELUT N/A
- EPS
- ACCS N/A
- ELUT N/A
- Revenue
- ACCS $21,332,000.00
- ELUT $21,746,000.00
- Revenue This Year
- ACCS $0.03
- ELUT $1.90
- Revenue Next Year
- ACCS $7.32
- ELUT $6.37
- P/E Ratio
- ACCS N/A
- ELUT N/A
- Revenue Growth
- ACCS 23.82
- ELUT N/A
- 52 Week Low
- ACCS $7.79
- ELUT $0.69
- 52 Week High
- ACCS $13.35
- ELUT $5.12
- Technical
- Relative Strength Index (RSI)
- ACCS 32.58
- ELUT 23.44
- Support Level
- ACCS $8.89
- ELUT $0.69
- Resistance Level
- ACCS $9.72
- ELUT $0.94
- Average True Range (ATR)
- ACCS 0.58
- ELUT 0.06
- MACD
- ACCS -0.02
- ELUT -0.01
- Stochastic Oscillator
- ACCS 4.05
- ELUT 17.80
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.